Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo …

…, AV Ramanan, S de Bono, CE Kartman… - The lancet Respiratory …, 2021 - thelancet.com
Background Baricitinib is an oral selective Janus kinase 1/2 inhibitor with known anti-inflammatory
properties. This study evaluates the efficacy and safety of baricitinib in combination …

[HTML][HTML] Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or …

EW Ely, AV Ramanan, CE Kartman… - The Lancet …, 2022 - thelancet.com
Background The oral, selective Janus kinase 1/2 inhibitor baricitinib has shown efficacy in
studies of hospitalised adults with COVID-19. COV-BARRIER (NCT04421027) was a …

[HTML][HTML] Evaluation of pneumococcal and tetanus vaccine responses in patients with rheumatoid arthritis receiving baricitinib: results from a long-term extension trial …

…, J Bradley, M Issa, R Klar, CE Kartman - Arthritis Research & …, 2019 - Springer
Background Clinical guidelines recommend pneumococcal and tetanus vaccinations in
patients with rheumatoid arthritis (RA). Baricitinib is an oral, selective Janus kinase (JAK) 1/JAK …

LB3. Baricitinib plus Standard of Care for Hospitalized Adults with COVID-19 on Invasive Mechanical Ventilation or Extracorporeal Membrane Oxygenation: Results of …

EW Ely, AV Ramanan, CE Kartman… - Open forum …, 2021 - academic.oup.com
Background Interventions to reduce mortality in critically ill patients with COVID-19 are a
crucial unmet medical need. Baricitinib (BARI) is an oral, selective Janus kinase (JAK)1/JAK2 …

Response to baricitinib based on prior biologic use in patients with refractory rheumatoid arthritis

MC Genovese, JM Kremer, CE Kartman… - …, 2018 - academic.oup.com
Objective RA patients who have failed biologic DMARDs (bDMARDs) represent an unmet
medical need. We evaluated the effects of baseline characteristics, including prior bDMARD …

[HTML][HTML] Baricitinib plus standard of care for hospitalized adults with COVID-19

VC Marconi, AV Ramanan, S de Bono, CE Kartman… - MedRxiv, 2021 - medrxiv.org
Background Baricitinib, an oral selective Janus kinase 1 and 2 inhibitor, improved outcomes
in a previous randomized controlled trial of hospitalized adults with COVID-19, in …

Efficacy and safety of baricitinib in patients with COVID-19 infection: results from the randomised, double-blind, placebo-controlled, parallel-group COV-BARRIER …

VC Marconi, AV Ramanan, S de Bono, CE Kartman… - MedRxiv, 2021 - medrxiv.org
Background The efficacy and safety of baricitinib, an oral selective Janus kinase 1/2 inhibitor,
in addition to standard of care (SOC) in hospitalised adults with COVID-19 is unknown. …

Radiographic progression of structural joint damage over 5 years of baricitinib treatment in patients with rheumatoid arthritis: Results from RA-BEYOND

D Van der Heijde, CE Kartman, L Xie… - The Journal of …, 2022 - jrheum.org
Objective To evaluate the effect of baricitinib on inhibiting radiographic progression of
structural joint damage over 5 years in patients with active rheumatoid arthritis (RA). Methods …

[HTML][HTML] Baricitinib in patients with rheumatoid arthritis and an inadequate response to conventional disease-modifying antirheumatic drugs in United States and rest of …

…, JD Bradley, J Alam, V Arora, CE Kartman - Rheumatology and …, 2018 - Springer
Introduction This article evaluates the efficacy and safety of baricitinib 4 mg versus placebo
in United States including Puerto Rico (US) and rest of the world (ROW) subpopulations …

P134 Radiographic progression of structural joint damage over 5 years of baricitinib treatment in patients with RA: results from RA-BEYOND

DMFM van der Heijde, CE Kartman, L Xie… - …, 2021 - academic.oup.com
Background/Aims Baricitinib (BARI) is an oral, reversible, selective JAK1/2 inhibitor. Treatment
with once-daily oral BARI resulted in low rates of radiographic progression for up to 2 …